Discovery and optimization of p38 inhibitors via computer-assisted drug design

Journal of Medicinal Chemistry

Volumn 50, Issue 17, 2007, Pages 4016-4026

  Goldberg, Daniel R ^a   Hao, Ming Hong ^a   Qian, Kevin C ^a   Swinamer, Alan D ^a   Gao, Donghong A ^a   Xiong, Zhaoming ^a   Sarko, Chris ^a   Berry, Angela ^a   Lord, John ^a   Magolda, Ronald L ^a,b   Fadra, Tazmeen ^a   Kroe, Rachel R ^a   Kukulka, Alison ^a   Madwed, Jeffrey B ^a   Martin, Leslie ^a   Pargellis, Christopher ^a   Skow, Donna ^a   Song, Jinhua J ^a   Tan, Zhulin ^a   Torcellini, Carol A ^a   Zimmitti, Clare S ^a   Yee, Nathan K ^a   Moss, Neil ^a   more..

^a BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 [(6 CYCLOPROPYLAMINOPYRIDINE 3 CARBONYL)AMINO] 1 METHYLINDOLE 2 CARBOXYLIC ACID (5 TERT BUTYL 3 METHANESULFONYLAMINO 2 METHOXYPHENYL)AMIDE; DORAMAPIMOD; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; N [2 (5 TERT BUTYL 3 METHANESULFONYLAMINO 2 METHOXYPHENYLCARBAMOYL) 1 METHYLINDOL 7 YL]NICOTINAMIDE; N [2 (5 TERT BUTYL 3 METHANESULFONYLAMINO 2 METHOXYPHENYLCARBAMOYL)BENZO[B]THIOPHEN 7 YL] 6 CYCLOPROPYLAMINONICOTINAMIDE; N [2 (5 TERT BUTYL 3 METHANESULFONYLAMINO 2 METHOXYPHENYLCARBAMOYL)BENZO[B]THIOPHEN 7 YL]NICOTINAMIDE; SORAFENIB; UNCLASSIFIED DRUG;

ARTICLE; COMPUTER AIDED DESIGN; DRUG CONFORMATION; DRUG DESIGN; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

ANIMALS; BINDING SITES; BIOLOGICAL AVAILABILITY; COMPUTER SIMULATION; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; LIPOPOLYSACCHARIDES; MALE; MICE; MODELS, MOLECULAR; NIACINAMIDE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN KINASE INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES; THIOPHENES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34548141772     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm070415w     Document Type: Article

References (28)

1. Imajo, M.; Tsuchiya, Y.; Nishida, E. Regulatory mechanisms and functions of MAP kinase signaling pathways. IUBMB Life 2006, 58 (5-6), 312-317.
2. Wagner, G.; Laufer, S. Small molecular anti-cytokine agents. Med. Res. Rev. 2005, 26 (11), 1-62.
3. (b) Calcagni, F.; Elenkov, I. Stress system activity, innate and T helper cytokines, and susceptibility to immune-related diseases. Ann. N.Y. Acad. Sci. 2006, 62-76.
4. Klinkhoff, A. Biological agents for rheumatoid arthritis: Targeting both physical function and structural damage. Drugs 2004, 64 (12), 1267-1283.
5. (b) Barry, J.; Kirby, B. Novel biologic therapies for psoriasis. Expert Opin. Biol. Ther. 2004, 6, 975-987.
6. (c) Elliott, M. J.; Maini, R. N.; Feldmann, M.; Kalden, J. R.; Antoni, C.; Smolen, J. S.; Leeb, B.; Breedveld, F. C.; Macfarlane, J. D.; Woody, J. N. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor a (cA2) versus placebo in rheumatoid arthritis. Lancet 1994, 344, 1105-1110.
7. (d) Cohen, S. B.; Woolley, J. M. Interleukin 1 receptor antagonist anakinra improves functional status in patients with RA. J. Rheumatol. 2003, 30, 225-231.
8. (e) Boehncke W. H.; Prinz, J.; Gottlieb, A. B. Biologic therapies for psoriasis. A systematic review. J. Rheumatol. 2006, 33 (7), 1447-1451.
9. Saklatvala, J. The p38 MAP kinase pathway as a therapeutic target in inflammatory disease. Curr. Opin. Pharmacol. 2004, 4 (4), 372-377.
10. Ashwell, J. D. The many paths to p38 mitogen-activated protein kinase activation in the immune system. Nat. Rev. Immunol. 2006, 6 (7), 532-540.
11. Pargellis, C.; Tong, L.; Churchill, L.; Cirillo, P. F.; Gilmore, T.; Graham, A. G.; Grab, P. M.; Hickey, E. R.; Moss, N.; Pav, S.; Regan, J. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat. Struct. Biol. 2002, 9 (4), 268-272.
12. (a) Dominguez, C.; Powers, D.; Tamayo, N. p38 MAP kinase inhibitors: Many are made, but few are chosen. Curr. Opin. Drug Discovery Dev. 2005, 8, 421-430.
13. (b) Cirillo P. F.; Pargellis, C.; Regan, J. The non-diaryl heterocycle classes of p38 MAP kinase inhibitors. Curr. Top. Med. Chem. 2002, 2 (9), 1021-1035.
14. Sullivan, J.; Holdgate, G. A.; Campbell, D.; Timms, D.; Gerhardt, S.; Breed, J.; Breeze, A. L.; Bermingham, A.; Pauptit, R. A.; Norman, R. A.; Embrey, K.; Read, J. Prevention of MKK6-dependent activation by binding to p38a MAP kinase. Biochemistry 2005, 44, 16475-16490.
15. (a) Schindler, T.; Bornmann, W.; Pellicena, P.; Miller, W. T.; Clarkson, B.; Kuriyan, J. Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase. Science 2000, 289 (5486), 1938-1942.
16. (b) Nagar, B.; Bornmann, W. G.; Pellicena, P.; Schindler, T.; Veach, D. R.; Miller, W. T.; Clarkson, B.; Kuriyan, J. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res. 2002, 62, 4236-4243.
17. (c) Tokarski, J. S.; Newitt, J. A.; Chang, C. Y. J.; Cheng, J. D.; Wittekind, M.; Kiefer, S. E.; Kish, K.; Lee, F. Y. F.; Borzillerri, R.; Lombardo, L. J.; Xie, D.; Zhang, Y.; Klei, H. E. The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against Imatinib-resistant ABL mutants. Cancer Res. 2006, 66, 5790-5797.
18. Regan, J.; Capolino, A.; Cirillo, P. F.; Gilmore, T.; Graham, A. G.; Hickey, E.; Kroe, R. R.; Madwed, J.; Moriak, M.; Nelson, R.; Pargellis, C. A.; Swinamer, A.; Torcellini, C.; Tsang, M.; Moss, N. Structure-activity relationships of the p38alpha MAP kinase inhibitor 1-(5-tert-butyl-2-p- tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl] urea (BIRB 796). J. Med. Chem. 2003, 46 (22), 4676-4686.
19. Niculescu-Duvaz, I.; Roman, E.; Whittaker, S. R.; Friedlos, F.; Kirk, R.; Scanlon, I. J.; Davies, L. C.; Niculescu-Duvaz, D.; Marais, R.; Springer, C. J. Novel inhibitors of bRAF based on a disubstituted pyrazine scaffold. Generation of a nanomolar lead. J. Med. Chem. 2006, 49 (1), 407-416.
20. Cirillo, P. F.; Hickey, E. Discovery of the N-phenyl- N′-naphthyl-urea class of p38 MAP kinase inhibitors. Results to be published at a later date.
21. Dominguez, C.; Tamayo, N.; Zhang, D. p38 Inhibitors: Beyond pyridinylimidazoles. Expert Opin. Ther. Pat. 2005, 15 (7), 801-816.
22. Wang, R.; Gao, Y.; Lai, L. LigBuilder: A multi-purpose program for structure-based drug design. J. Mol. Model. 2000, 6, 498-516.
23. Rahaman, L. K. A.; Scrowston, R. A. 7-Substituted benzo[b]- thiophenes and 1,2-benzisothiazoles. Part 2. Chloro and nitro derivatives. J. Chem. Soc., Perkin Trans. 1 1984, 19, 385-387.
24. For this series, a 2.8°C change in thermal denaturation temperature corresponds to approximately a 10-fold change in binding affinity. However, it must be noted that this equation was developed for pyrazole naphthyl urea-based inhibitors (e.g., 1), and if the thermodynamics of binding for this class of inhibitors is significantly different, this relationship may be more of an approximation. Kroe, R. R.; Regan, J.; Proto, A.; Peet, G. W.; Roy, T.; Dickert, L.; Fuschetto, N.; Pargellis, C. A.; Ingraham, R. H. Thermal denaturation: A method to rank slow binding, high-affinity p38a MAP kinase inhibitors. J. Med. Chem. 2003, 46 (22), 4669-4675.
25. (a) Liu, C.; Wrobleski, S. T.; Lin, J.; Ahmed, G.; Metzger, A.; Wityak, J.; Gillooly, K. M.; Shuster, D. J.; McIntyre, K. W.; Pitt, S.; Shen, D. R.; Zhang, R. F.; Zhang, H.; Doweyko, A. M.; Diller, D.; Henderson, I.; Barrish, J. C.; Dodd, J. H.; Schieven, G. L.; Leftheris, K. 5-Cyanopyrimidine derivatives as a novel class of potent, selective, and orally active inhibitors of p38α MAP kinase. J. Med. Chem. 2005, 48 (20), 6261-6270.
26. (b) Johnson, L. N.; De Moliner, E.; Brown, N. R.; Song, H.; Barford, D.; Endicott, J. A.; Noble, M. E. Structural studies with inhibitors of the cell cycle regulatory kinase cyclin-dependent protein kinase 2. Pharmacol. Ther. 2002, 93 (2-3), 113-124.
27. Liverton, N. J.; Butcher, J. W.; Claiborne, C. F.; Claremon, D. A.; Libby, B. E.; Nguyen, K. T.; Pitzenberger, S. M.; Selnick, H. G.; Smith, G. R.; Tebben, A.; Vacca, J. P.; Varga, S. L.; Agarwal, L.; Dancheck, K.; Forsyth, A. J.; Fletcher, D. S.; Frantz, B.; Hanlon, W. H.; Harper, C. F.; Hofsess, S. J.; Kostura, M.; Lin, J.; Luell, S.; O'Neill, E. A.; Orevillo, C. J.; Pang, M.; Parsons, J.; Rolando, A.; Sahly, Y.; Visco, D. M.; O'Keefe, S. J. Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase. J. Med. Chem. 1999, 42 (12), 2180-2190.
28. Carter, T.A.; Wodicka, L. M.; Shah, N. P.; Velasco, A. M.; Fabian, M. A.; Treiber, D. K.; Milanov, Z. V.; Atteridge, C. E.; Biggs, W. H., III; Edeen, P. T.; Floyd, M.; Ford, J. M.; Grotzfeld, R. M.; Herrgard, S.; Insko, D. E.; Mehta, S. A.; Patel, H. K.; Pao, W.; Sawyers, C. L.; Varmus, H.; Zarrinkar, P. P.; Lockhart, D. J. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc. Natl. Acad. Sci. U.S.A. 2005, 102 (31), 11011-11016.